Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

Cumulus Neuroscience Ireland Massachusetts

Data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) Annual Meeting provides further validation of the utility of Cumulus Neuroassessment Platform in clinical studies that include patients with mild to moderate cognitive impairment.View original content:https://www.prnewswire.co.uk/news-releases/cumulus-neuroscience-presents-data-at-ctad-2023-annual-meeting-301966499.html